Word

ADCT

Status

Pending

Status Code

732

Status Date

Tuesday, January 16, 2024

Serial Number

90191738

Mark Type

4000

Filing Date

Friday, September 18, 2020

Published for Opposition

Tuesday, May 24, 2022

Trademark Owner History

ADC Therapeutics SA - Owner At Publication

Classifications

5 Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in the prevention and treatment of cancer and tumors; pharmaceutical preparations for use in the prevention and treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, pharmaceutical antibodies; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations, biological preparations, and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans

44 Providing medical information; providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, health, and wellness

42 Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals; Providing medical and scientific research information in the fields of clinical trials; scientific study and research in the field of pharmaceuticals for the treatment of cancer

Trademark Events

Jan 18, 2024

Notice Of Approval Of Extension Request E-Mailed

Jan 16, 2024

Sou Extension 3 Granted

Jan 16, 2024

Sou Extension 3 Filed

Jan 16, 2024

Sou Teas Extension Received

Jul 15, 2023

Notice Of Approval Of Extension Request E-Mailed

Jul 13, 2023

Sou Extension 2 Granted

Jul 13, 2023

Sou Extension 2 Filed

Jul 13, 2023

Sou Teas Extension Received

Jan 20, 2023

Notice Of Approval Of Extension Request E-Mailed

Jan 18, 2023

Sou Extension 1 Granted

Jan 18, 2023

Sou Extension 1 Filed

Jan 18, 2023

Sou Teas Extension Received

Jul 19, 2022

Noa E-Mailed - Sou Required From Applicant

May 24, 2022

Official Gazette Publication Confirmation E-Mailed

May 24, 2022

Published For Opposition

May 4, 2022

Notification Of Notice Of Publication E-Mailed

Apr 20, 2022

Exparte Appeal Terminated

Apr 20, 2022

Approved For Pub - Principal Register

Apr 12, 2022

Teas/Email Correspondence Entered

Apr 12, 2022

Correspondence Received In Law Office

Apr 11, 2022

Assigned To Lie

Apr 6, 2022

Teas Request For Reconsideration Received

Apr 6, 2022

Ex Parte Appeal-Instituted

Apr 6, 2022

Jurisdiction Restored To Examining Attorney

Apr 6, 2022

Exparte Appeal Received At Ttab

Oct 6, 2021

Notification Of Final Refusal Emailed

Oct 6, 2021

Final Refusal E-Mailed

Oct 6, 2021

Final Refusal Written

Aug 3, 2021

Teas/Email Correspondence Entered

Aug 3, 2021

Correspondence Received In Law Office

Aug 3, 2021

Teas Response To Office Action Received

Feb 3, 2021

Notification Of Non-Final Action E-Mailed

Feb 3, 2021

Non-Final Action E-Mailed

Feb 3, 2021

Non-Final Action Written

Feb 2, 2021

Assigned To Examiner

Oct 28, 2020

New Application Office Supplied Data Entered

Sep 22, 2020

New Application Entered